Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, 519000, China.
BMC Pulm Med. 2024 Aug 29;24(1):422. doi: 10.1186/s12890-024-03237-w.
In this study, we aimed to evaluate the clinical utility of Metagenomic Next-Generation sequencing (mNGS) on bronchoalveolar lavage fluid (BALF) in diagnosis of Lower Respiratory Tract Infections (LRTIs).
In this study, we retrospectively analyzed 186 hospitalized patients who were suspected with LRTIs and performed mNGS (DNA) test of BALF simultaneously at The Fifth Affiliated Hospital of Sun Yat-Sen University from March 2023 to August 2023. Suspected LRTI was based on LRTI related clinical manifestations or imaging examination. Among them, 155 patients had undergone conventional culture and mNGS (DNA) testing simultaneously. Finally, 138 cases (89.03%,138/155) were diagnosed as LRTI and 17 cases (10.97%,17/155) were diagnosed as non-LRTI. Both detecting rate and diagnostic efficacy of mNGS and conventional culture were compared.
The positive detection rates of pathogens between mNGS and conventional culture were significant different (81.29% VS 39.35%, P < 0.05). Compared with paired conventional culture result, the sensitivity of mNGS in diagnosis of LRTIs was more superior (88.41% VS 43.48%; P < 0.05), the specificity was opposite (76.47% VS 94.12%; P > 0.05). Furthermore, 77.54% and 35.51% of LRTI cases were being etiologically diagnosed by mNGS and culture respectively. Importantly, mNGS directly led to a change of treatment regimen in 58 (37.42%) cases, including antibiotic adjustment (29.68%) and ruling out active infection (7.74%). Moreover, treatment regimen remained unchanged in 97 (62.58%) cases, considering the current antibiotic therapy already covered the detected pathogens (36.13%) or empirical treatment was effective (11.61%).
mNGS can identify a wide range of pathogens in LRTIs, with improved sensitivity and being more superior at diagnosing LRTIs etiologically. mNGS has the potential to enhance clinical outcomes by optimizing the treatment regimens.
本研究旨在评估宏基因组下一代测序(mNGS)在支气管肺泡灌洗液(BALF)中对下呼吸道感染(LRTI)的临床应用价值。
本研究回顾性分析了 2023 年 3 月至 2023 年 8 月中山大学附属第五医院收治的 186 例疑似 LRTI 患者,这些患者同时进行了 mNGS(DNA)检测。疑似 LRTI 基于 LRTI 相关的临床表现或影像学检查。其中,155 例患者同时进行了常规培养和 mNGS(DNA)检测。最终,138 例(89.03%,138/155)被诊断为 LRTI,17 例(10.97%,17/155)被诊断为非 LRTI。比较 mNGS 和常规培养的检出率和诊断效能。
mNGS 和常规培养的病原体阳性检出率差异有统计学意义(81.29% VS 39.35%,P<0.05)。与配对的常规培养结果相比,mNGS 对 LRTIs 的诊断敏感性更高(88.41% VS 43.48%;P<0.05),特异性相反(76.47% VS 94.12%;P>0.05)。此外,mNGS 分别对 77.54%和 35.51%的 LRTI 病例进行了病因学诊断。重要的是,mNGS 直接导致 58 例(37.42%)治疗方案发生改变,包括抗生素调整(29.68%)和排除活动性感染(7.74%)。此外,97 例(62.58%)患者的治疗方案保持不变,因为当前的抗生素治疗已经覆盖了检测到的病原体(36.13%)或经验性治疗有效(11.61%)。
mNGS 可识别 LRTI 中的多种病原体,提高诊断 LRTI 的敏感性和病因学诊断能力。mNGS 有可能通过优化治疗方案来改善临床结局。